



U.S. Fish & Wildlife Service

The Aquatic Animal Drug Approval Partnership Program

Fact Sheet: SLICE[®] INAD 11-370

INAD objective/purpose:	Collect scientific data necessary to establish the effectiveness AND safety of SLICE [®] to control mortality caused by external parasites in a variety of freshwater fish species.
Drug name:	SLICE [®] (emamectin benzoate; 0.2% aquaculture premix)
Source of drug:	Merck Animal Health
Address:	35500 W. 91 st Street De Soto, KS 66018
Contact:	Kasha M. Cox Phone: 662-907-0692; email: kasha.cox@merck.com
Target pathogen(s):	parasitic copepods
Method of administration:	Medicated feed treatment
Treatment dosage:	50 micrograms (µg) emamectin benzoate per kilogram (kg) of fish biomass per day
Treatment regimen:	7 consecutive days SLICE [®] should be administered as a single treatment event, with no repetition of treatment.
Withdrawal period:	60 days
Required test parameters:	Investigator must collect mortality data throughout the 5 day pre-treatment, treatment, and 28 day post-treatment periods. Note: SLICE doesn't usually reach fully efficacy until 20-30 days after treatment depending on water temp. The case history and analyses of parasite load needs to be checked both pre- and post-treatment. Investigator must also report general fish behavior and any adverse effects relating to treatment.
Limitations or restrictions on use of drug:	Investigator must follow all instructions in the Study Protocol for INAD 11-370 regarding drug acquisition and handling, fish treatment and disposition, and data reporting requirements. Investigator must complete Facility Effluent Information Form and obtain NPDES acknowledgement/permission for discharge of SLICE[®] before use under the INAD. Contact AADAP for more information.
Required INAD fee:	\$700.00/facility/year
AADAP Contact Information:	Ms. Bonnie Johnson, FWS-AADAP Phone: 406-994-9905 Fax: 406-582-0242 email: bonnie_johnson@fws.gov